Regulation & Patient Safety

Quality is built into the process, not added at the end.

Patient safety depends on disciplined systems that begin with qualified materials, continue through controlled compounding and monitoring, and conclude with an appropriate review before release.

The exact controls, testing, and regulatory requirements depend on the formulation and whether the request follows the 503A or 503B pathway.

Explore Our Quality System Licensing & Compliance

A quality system in practice

Qualified materials

Ingredient identity, supplier documentation, and applicable specifications establish the starting point.

Controlled environments

Facility controls, cleaning, personnel practices, and monitoring help reduce preventable risks.

Documented processes

Established procedures and production records support consistency, traceability, and review.

Appropriate release review

Documentation and applicable test results are evaluated before a preparation or batch is released.

Quality System

Controls that work together

Quality is not defined by one room, one test, or one review. It is supported by connected controls across sourcing, preparation, monitoring, documentation, testing, and release.

The scope of each control is determined by the product, facility, service pathway, and applicable regulatory requirements.

Quality Assurance

Quality built into the process

Documented procedures, production records, in-process controls, and quality review support consistency from material receipt through final disposition. The exact review and release requirements depend on the formulation and service pathway.

API Sourcing

Quality begins with qualified ingredients

Active pharmaceutical ingredients and other components are sourced through qualified suppliers and evaluated using documentation such as certificates of analysis, identity requirements, and applicable compendial or regulatory specifications.

Sterile Operations

Controlled production environments

Sterile compounding relies on controlled environments supported by cleaning and disinfection procedures, personnel qualification, process controls, and practices designed to reduce contamination risk.

Environmental Monitoring

Ongoing oversight of critical conditions

Routine environmental monitoring helps evaluate conditions within sterile areas. Results can be reviewed and trended so excursions are investigated and addressed through documented quality processes.

Laboratory Testing

Independent verification where applicable

Third-party laboratory testing may include potency, sterility, bacterial endotoxins, or other attributes appropriate to the formulation and release plan. Testing requirements differ by product, batch type, and regulatory pathway.

Stability & Dating

Beyond-use dates supported by evidence

Beyond-use dating considers applicable standards, formulation characteristics, storage conditions, and available stability information. Extended dating should be supported by appropriate scientific data and testing.

Regulatory Framework

The applicable standard depends on the pathway

503A pharmacy compounding and 503B outsourcing operate under different federal frameworks. Quality language should reflect that distinction rather than treating every service as identical.

Compare 503A and 503B

503A Pharmacy Operations

Patient-specific compounding standards

503A compounding is performed by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a licensed physician. When all conditions of section 503A are met, compounded drugs are exempt from federal CGMP and premarket approval requirements.

Applicable state pharmacy law and compounding standards, including relevant USP requirements, remain central to the operating framework.

View the 503A pathway

503B Outsourcing Operations

CGMP and outsourcing-facility requirements

A 503B outsourcing facility registers with FDA and compounds under the direct supervision of a licensed pharmacist. Outsourcing facilities must comply with federal CGMP requirements and are inspected by FDA according to a risk-based schedule.

Additional requirements include product reporting, adverse-event reporting, labeling, and other conditions under section 503B.

View the 503B pathway

Compounded medications are not FDA-approved and do not undergo FDA premarket review for safety, effectiveness, or quality. Registration, licensure, or compliance with an applicable pathway should not be described as FDA approval.

Quality Documentation

Clear documentation supports better decisions

Providers, pharmacies, and facility buyers should be able to ask direct questions about the documentation, storage conditions, testing, and support associated with a specific product.

Documentation availability and format can vary by formulation, product, batch, and service pathway.

Product and release documentation

Ask about certificates of analysis, lot-specific release documentation, or testing summaries when they are available and appropriate to the product.

Storage and handling guidance

Confirm required storage temperatures, shipping conditions, handling instructions, and the appropriate response to a potentially compromised shipment.

Dating and use instructions

Review the labeled beyond-use date, storage requirements, and any formulation-specific preparation or handling instructions before use.

Quality concerns and reportable events

Use established support channels to report product-quality concerns, adverse events, temperature excursions, damaged shipments, or potential recall questions.

Contact our team with a product-specific quality, handling, or documentation question.

Contact TruPharmaRx